Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The noradrenaline receptor alpha 1B, also known as the alpha-1B adrenergic receptor or ADRA1B, is a member of the G protein-coupled receptor (GPCR) superfamily. It is one of three subtypes of alpha-1 adrenergic receptors, all of which are activated by catecholamines such as norepinephrine (noradrenaline) and epinephrine (adrenaline). It is widely distributed in the body, with high expression levels in the central nervous system. Upon activation, it stimulates phospholipase C, leading to increased production of IP3 and DAG, resulting in elevated intracellular calcium levels and activation of protein kinase C pathways. It primarily mediates smooth muscle contraction, notably vasoconstriction. ADRA1B has been implicated as a proto-oncogene and interacts with proteins such as AP2M1. Mutations can result in constitutive activity.
Agonism/Antagonism of alpha-1B adrenergic receptor
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Noradrenaline Receptor Alpha 1B (ADRA1B).